BioCentury
ARTICLE | Clinical News

Droxidopa: Phase II started

February 2, 2009 8:00 AM UTC

Chelsea began a double-blind, U.K. Phase II trial in 120 patients. The 12-arm study is designed to evaluate 200, 400 or 600 mg of oral droxidopa given 3 times daily; 25 or 50 mg carbidopa given 3 time...